Desjardins Securities upgraded Dexcom (NASDAQ:DXCM) from Hold to Buy in a statement released earlier today.
- Updated: September 16, 2016
Desjardins Securities has upgraded Dexcom(NASDAQ:DXCM) from Hold to Buy in a statement released on Friday September 16 2016.
Yesterday Dexcom (NASDAQ:DXCM) traded 1.18% higher at $93.84. Dexcom’s 50-day average is $91.68 and its 200-day average is $75.01. With the last close up 25.11% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same time. Trade volume was was down over the average, with 81,862 shares of DXCM changing hands under the typical 840,834 shares..
Recent Performance Graphic:
Dexcom has a one-year low of $47.92 and a 52 week high of $102.67. The company’s market cap is currently $0.0.
Brief Synopsis On Dexcom (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, and enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient’s receiver and a mobile application on the patient’s iPhone to transmit glucose information.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.